US4196191A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biological preparations
Assignee: SmithKline Beecham Corp
•
Filing: 1979-03-30
•
Granted: 1980-04-01
•
Expires: 1999-03-30
Abstract
Abstract A novel antigenic preparation which comprises a plurality of microvesicles which microvesicles are unilamellar bodies comprising a single lipid bilayer upon the exterior surface of which is bound an antigenic protein derived from a virus and having a hydrophobic region.
Inventors
- 👤 June D. Almeida
- 👤 David C. Edwards
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:44
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/39; A61K9/00; A61K9/10; A61K9/127; A61K9/1271; A61K2039/555; A61K2039/55511; A61K2039/55555; Y; Y10; Y10S; Y10S424/00; Y10S424/812
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
61 words
An antigenic virosome preparation containing a plurality of microvesicles which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a haemagglutinin sub-unit of protective surface antigen derived from a virus selected from a measles virus and a corona virus, and having hydrophobic region.
Claim 2
Dependent Claim
61 words
An antigenic virosome preparation containing a plurality of microvesicles which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a haemagglutinin sub-unit of protective surface antigen derived from a virus selected from a measles virus and a corona virus, and having hydrophobic region.
Claim 3
Dependent Claim
20 words
An antigenic virosome preparation as claimed in claim 1 wherein the protective surface antigen is derived from a corona virus.
Claim 4
Dependent Claim
20 words
An antigenic virosome preparation as claimed in claim 1 wherein the protective surface antigen is derived from a measles virus.
Claim 5
Dependent Claim
17 words
An antigenic virosome preparation as claimed in claim 1 wherein the walls of the microvesicles contain lecithin.
Claim 6
Dependent Claim
17 words
An antigenic virosome preparation as claimed in claim 1 wherein the microvesicles contain cholesterol as a strengthener.
Claim 7
Dependent Claim
16 words
An antigenic virosome preparation as claimed in claim 1 wherein the microvesicles encapsulate an additional adjuvant.
Claim 8
Dependent Claim
23 words
An antigenic virosome preparation as claimed in claim 1 wherein the microvesicles are in the size range of 20 nm to 100 nm.
Claim 9
Dependent Claim
75 words
A pharmaceutical formulation which comprises an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a haemagglutinin sub-unit of a protective surface antigen derived from a virus selected from a measles virus and a corona virus, and having a hydrophobic region, in association with an acceptable carrier therefor.
Claim 10
Dependent Claim
75 words
A pharmaceutical formulation which comprises an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a haemagglutinin sub-unit of a protective surface antigen derived from a virus selected from a measles virus and a corona virus, and having a hydrophobic region, in association with an acceptable carrier therefor.
Claim 11
Dependent Claim
17 words
A formulation according to claim 8 wherein the protective surface antigen is derived from a corona virus.
Claim 12
Dependent Claim
17 words
A formulation according to claim 8 wherein the protective surface antigen is derived from a measles virus.
Claim 13
Dependent Claim
12 words
A formulation according to claim 8 wherein the carrier comprises a liquid.
Claim 14
Dependent Claim
10 words
A formulation according to claim 8 in unit dosage form.
Claim 15
Dependent Claim
19 words
A formulation according to claim 8 which is suitable for administration by a route selected from nasal and parenteral.
Claim 16
Independent Claim
83 words
A method for inducing antibody formation in a mammal which comprises the administration to the mammal of a non-toxic antibody stimulating amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein being a haemagglutinin sub-unit of a protective surface antigen derived from a virus selected from a measles virus and a corona virus, and having a hydrophobic region.
Claim 17
Independent Claim
83 words
A method for inducing antibody formation in a mammal which comprises the administration to the mammal of a non-toxic antibody stimulating amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein being a haemagglutinin sub-unit of a protective surface antigen derived from a virus selected from a measles virus and a corona virus, and having a hydrophobic region.
Claim 18
Dependent Claim
17 words
A method according to claim 14 wherein the protective surface antigen is derived from a measles virus.
Claim 19
Dependent Claim
54 words
An antigenic virosome preparation containing a pluraltiy of microvesicles which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a sub-unit of a protective surface antigen derived from a herpes virus and having a hydrophobic region.
Claim 20
Dependent Claim
54 words
An antigenic virosome preparation containing a pluraltiy of microvesicles which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a sub-unit of a protective surface antigen derived from a herpes virus and having a hydrophobic region.
Claim 21
Dependent Claim
19 words
An antigenic virosome preparation as claimed in claim 16 wherein the protective surface antigen is derived from a cytomegalovirus.
Claim 22
Dependent Claim
66 words
A pharmaceutical formulation which comprises an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a sub-unit of a protective surface antigen derived from a herpes virus and having a hydrophobic region, in association with an acceptable carrier therefor.
Claim 23
Dependent Claim
66 words
A pharmaceutical formulation which comprises an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein, said antigenic protein being a sub-unit of a protective surface antigen derived from a herpes virus and having a hydrophobic region, in association with an acceptable carrier therefor.
Claim 24
Dependent Claim
16 words
A formulation according to claim 18 wherein the protective surface antigen is derived from a cytomegalovirus.
Claim 25
Independent Claim
74 words
A method for inducing antibody formation in a mammal which comprises the administration to the mammal of a non-toxic antibody stimulating amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein being a sub-unit of a protective surface antigen derived from a herpes virus and having a hydrophobic region.
Claim 26
Independent Claim
74 words
A method for inducing antibody formation in a mammal which comprises the administration to the mammal of a non-toxic antibody stimulating amount of an antigenic virosome preparation containing a plurality of microvesicles, which microvesicles are unilamellar bodies having a single lipid bilayer upon the exterior surface of which is bound by hydrophobic bonding an antigenic protein being a sub-unit of a protective surface antigen derived from a herpes virus and having a hydrophobic region.
Claim 27
Dependent Claim
16 words
A method according to claim 20 wherein the protective surface antigen is derived from a cytomegalovirus.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-04-01 | 1983-10-01 | 1984-04-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-04-01 | 1987-10-01 | 1988-04-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-04-01 | 1991-10-01 | 1992-04-01 | $7700.00 | Window Closed / Lapsed |